Premium
Safe and effective administration of BCG for bladder carcinoma in situ after umbilical cord blood stem cell transplantation
Author(s) -
Magaribuchi Toshihiro,
Akamatsu Shusuke,
Kobayashi Takashi,
Kawabata Hiroshi,
Yamasaki Toshinari,
Inoue Takahiro,
Ogawa Osamu
Publication year - 2017
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12758
Subject(s) - medicine , umbilical cord , carcinoma in situ , transplantation , stem cell , bladder cancer , carcinoma , surgery , urology , cord blood , transitional cell carcinoma , cancer , oncology , immunology , biology , genetics
Although intravesical Bacillus Calmette‐Guérin ( BCG ) instillation is the standard treatment for carcinoma in situ of the bladder, it is generally contraindicated in immunocompromised patients. Here we report the first case, to our knowledge, of BCG treatment for a bladder cancer patient who had received umbilical cord blood stem cell transplantation ( UCBSCT ). BCG can be given safely and effectively in select cases where reconstitution of the immune system has been achieved at least 2 years after UCBSCT .